Evaluation of the Effect of α-L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property.

CONCLUSION: This study revealed that G2013, as a novel NSAID with the immunomodulatory property, is able to reduce the gene expression and activity of COX-1/COX-2 enzymes. According to the findings, this agent might be categorized and introduced as a novel NSAID for the treatment of inflammatory diseases. PMID: 29879894 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29879894?dopt=Abstract

Source: Recent Patents on Inflammation and Allergy Drug Discovery - June 10, 2018 Category: Allergy & Immunology Tags: Recent Pat Inflamm Allergy Drug Discov Source Type: research